Published in Cancer Res on August 06, 2015
DNA methylation outliers in normal breast tissue identify field defects that are enriched in cancer. Nat Commun (2016) 0.93
Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness. Virchows Arch (2016) 0.78
In utero exposure of rats to high-fat diets perturbs gene expression profiles and cancer susceptibility of prepubertal mammary glands. J Nutr Biochem (2015) 0.77
Leveraging premalignant biology for immune-based cancer prevention. Proc Natl Acad Sci U S A (2016) 0.75
Gene-set Analysis with CGI Information for Differential DNA Methylation Profiling. Sci Rep (2016) 0.75
Induced p53 loss in mouse luminal cells causes clonal expansion and development of mammary tumours. Nat Commun (2017) 0.75
Molecular classification of non-invasive breast lesions for personalised therapy and chemoprevention. Oncotarget (2015) 0.75
Cancer stem cells and early stage basal-like breast cancer. World J Obstet Gynecol (2016) 0.75
Disease evolution and heterogeneity in bilateral breast cancer. Am J Cancer Res (2016) 0.75
Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition. Cancer Discov (2017) 0.75
The lncRNA BORG Drives Breast Cancer Metastasis and Disease Recurrence. Sci Rep (2017) 0.75
Epigenetic Silencing of MORT Is an Early Event in Cancer and Is Associated with Luminal, Receptor Positive Breast Tumor Subtypes. J Breast Cancer (2017) 0.75
TopHat: discovering splice junctions with RNA-Seq. Bioinformatics (2009) 81.13
edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics (2009) 67.17
A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet (2011) 59.36
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res (2010) 43.51
TM4: a free, open-source system for microarray data management and analysis. Biotechniques (2003) 38.02
Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature (2010) 23.55
Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 22.22
Signatures of mutational processes in human cancer. Nature (2013) 21.63
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47
GREAT improves functional interpretation of cis-regulatory regions. Nat Biotechnol (2010) 16.72
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. Bioinformatics (2011) 9.79
Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics (2010) 8.44
Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer (1999) 4.70
Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature (2000) 3.78
Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res (2007) 3.76
A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol (2008) 3.02
Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun (2013) 2.94
Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics (2011) 2.86
A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst (2013) 2.56
Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation. Oncogene (1998) 2.28
A myelopoiesis-associated regulatory intergenic noncoding RNA transcript within the human HOXA cluster. Blood (2009) 2.18
Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer (1995) 2.01
Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci U S A (2011) 1.78
miR-22 represses cancer progression by inducing cellular senescence. J Cell Biol (2011) 1.78
Identification of new microRNAs in paired normal and tumor breast tissue suggests a dual role for the ERBB2/Her2 gene. Cancer Res (2011) 1.70
p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast. J Natl Cancer Inst (2001) 1.67
Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res (2006) 1.59
Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin Cancer Res (2008) 1.50
PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res (2010) 1.49
Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. Mol Oncol (2010) 1.45
An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples. FEBS J (2010) 1.36
Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes. Oncotarget (2014) 1.34
Epidemiology of ductal carcinoma in situ. J Natl Cancer Inst Monogr (2010) 1.33
HOXA5 regulates expression of the progesterone receptor. J Biol Chem (2000) 1.28
Heterogeneity of ductal carcinoma in situ and its effects on management. Lancet Oncol (2006) 1.25
Patterns of chromosomal alterations in breast ductal carcinoma in situ. Clin Cancer Res (2004) 1.20
Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. Br J Cancer (2010) 1.19
Ductal carcinoma in situ: terminology, classification, and natural history. J Natl Cancer Inst Monogr (2010) 1.16
Molecular markers for the diagnosis and management of ductal carcinoma in situ. J Natl Cancer Inst Monogr (2010) 1.15
Noncoding RNAs and enhancers: complications of a long-distance relationship. Trends Genet (2011) 1.13
Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomas. Hum Pathol (2012) 1.11
Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer. Breast Cancer Res Treat (2009) 1.08
miR-17/20 sensitization of breast cancer cells to chemotherapy-induced apoptosis requires Akt1. Oncotarget (2014) 0.92
SOX15 is a candidate tumor suppressor in pancreatic cancer with a potential role in Wnt/β-catenin signaling. Oncogene (2013) 0.90
Breast cancer. Dare to do less. Science (2014) 0.88
SOX10, a novel HMG-box-containing tumor suppressor, inhibits growth and metastasis of digestive cancers by suppressing the Wnt/β-catenin pathway. Oncotarget (2014) 0.84
The HER2-encoded miR-4728-3p regulates ESR1 through a non-canonical internal seed interaction. PLoS One (2014) 0.82
Radiation therapy for ductal carcinoma in situ: is it really worth it? J Clin Oncol (2007) 0.80
Re: Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst (2011) 0.78
Risk of recurrence of ductal carcinoma in situ by oncotype Dx technology: some concerns. Cancer (2013) 0.77